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during the 4 hours after Sr administration 2867 6 1101 FAD%No difference in intestinal strontium absorption after oral or
(fraction of the absorbed dose) vs. 3117 6 1581 FAD% withIV calcitriol in children with secondary hyperparathyroidism.
oral and IV calcitriol, respectively]. The calcitriol-stimulated SrBackground. Oral and intravenous calcitriol bolus therapy
absorption was more then 30% higher compared with controlare both recommended for the treatment of secondary hyper-
values (2165 6 176 FAD%). A significant decrease in plasmaparathyroidism, but it has been claimed that the latter is less
iPTH was noted 12 hours after the administration of thelikely to induce absorptive hypercalcemia. The present study
calcitriol bolus, which was maintained for up to 72 hours with-was undertaken to verify whether intravenous calcitriol actually
out any differences regarding the two routes of administration.stimulates intestinal calcium absorption less than oral calcitriol
Conclusions. These results demonstrate that under acuteand whether it is superior in suppressing parathyroid hormone
conditions, intravenous and oral calcitriol boli equally stimulate(PTH) secretion.
calcium absorption and had a similar efficacy in suppressingMethods. Twenty children (16 males, age range of 5.1 to 16.9
PTH secretion.years, mean creatinine clearance 21.9 6 11.5 mL/min/1.73 m2,
range of 7.4 to 52.7) with chronic renal failure (CRF) and
secondary hyperparathyroidism [median intact PTH (iPTH),
327 pg/mL; range 143 to 1323] received two single calcitriol Secondary hyperparathyroidism remains a significantboli (1.5 mg/m2 body surface area) orally and intravenously
therapeutic problem in patients with chronic renal failureusing a randomized crossover design. iPTH and 1,25(OH)2D3
(CRF) [1, 2], particularly in children who are susceptiblelevels were measured over 72 hours, and intestinal calcium
absorption was measured 24 hours after the calcitriol bolus to a rapid appearance of skeletal deformities and stunt-
using stable strontium (Sr) as a surrogate marker. Baseline ing [3]. Calcitriol is considered to be an important part
control values for Sr absorption were obtained in a separate
of the standard treatment of secondary hyperparathy-group of children with CRF of similar severity.
roidism. It lowers parathyroid hormone (PTH) secretionResults. The peak serum level of 1,25(OH)2D3 and area un-
der the curve baseline to 72 hours (AUC0–72h) were significantly by increasing the serum calcium concentration and by
higher after intravenous (IV) calcitriol (AUC0–72h oral, 1399 6 decreasing the expression of pre-pro-PTH mRNA [4–6].
979 pg/mL · hour vs. IV 2793 6 1102 pg/mL · hour, P , 0.01), but It also suppresses parathyroid cell proliferation [7], thus
the mean intestinal Sr absorption was not different [SrAUC0–240 min preventing parathyroid gland hyperplasia [7, 8]. A single
dose of calcitriol results in a prolonged suppression of
1 European Study Group on Vitamin D in Children with Renal Failure PTH mRNA [4] and a prolonged decrease of plasma intact
(other than the writing committee): K. Michelis (Athens, Greece), P. Sally PTH (iPTH) in patients [9, 10]. Intravenous calcitriol
(Budapest, Hungary), D. Drozdz (Cracow, Poland), E. Bonzel (Essen,
bolus therapy [11] given one to three times per week hasGermany), A. Zurowska (Gdansk, Poland), F. Perfumo (Genoa, Italy),
U. Berg (Huddinge, Sweden), L. Barletta, F. Campanini, S. Testa, S. been proposed as the treatment of choice. The efficacy of
Tirelli (Milan, Italy), M.L. Murer (Padova, Italy), J. Dusek (Prague, this treatment modality has been ascribed to the high
Czech Republic), M. Fishbach (Strasbourg, France), S. Picca (Rome,
peak concentration of calcitriol, which may saturate theItaly), M. Wigger (Rostock, Germany), and T. Neuhaus (Zurich, Swit-
zerland). calcitriol receptor completely. Several clinical studies
have proven the efficacy of intravenous (IV) bolus ther-Key words: vitamin D, 1,25(OH)2D3, intact PTH, calcium absorption,
apy [12, 13]. However, not only IV bolus therapy buthypercalcemia, parathyroid hormone, skeletal deformities in children,
chronic renal failure. also intramuscular [14] and oral bolus therapies [15–17]
have been shown to be effective. The clinical use ofReceived for publication August 7, 1998
calcitriol is limited by hypercalcemia and hyperphospha-and in revised form March 15, 2000
Accepted for publication March 20, 2000 temia, and it has been claimed that this risk is decreased
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Fig. 1. Study design (Sr test, strontium absorption test).
of any direct contact between calcitriol and mucosal epi- Baseline control Sr absorption without calcitriol was
measured in five additional children with CRF usingthelial cells during the process of intestinal absorption.
The efficacy and safety of intravenous and oral bolus identical inclusion criteria for selection. These patients
had a mean age of 13.4 6 3.1 years, and a mean creatininetherapy have been compared in uncontrolled and head-
on comparison studies [16, 18, 19], but no definite conclu- clearance of 31.5 6 16.5 mL/min/1.73 m2.
sions can be drawn from these studies regarding differen-
tial effects on calcium absorption and the consequent
Study protocolrisk of hypercalcemia.
Study design. The study was designed as a multicenter,The present study was designed to compare the effects
prospective, stratified and randomized study with a cross-of a single oral and IV calcitriol bolus on plasma iPTH
over design for treatment modalities: (1) an initial three-levels and on the intestinal calcium absorption of chil-
week run-in (washout) period; (2) the first calcitriol bolusdren and adolescents with secondary hyperparathyroid-
given orally or intravenously (according to the random-ism. Stable strontium (Sr) was used as a surrogate marker
ization schedule); (3) a second washout period of threefor calcium [20–24].
weeks; and (4) the second IV or oral calcitriol bolus
(Fig. 1). The group of patients recruited for the baseline
METHODS control Sr test underwent a run-in period, at the end of
Patients which the Sr test was performed without administering
calcitriol.Twenty patients were recruited from eight pediatric
The study protocol was approved by the Ethics Com-nephrology units. The entry criteria included an age be-
mittee of the University of Heidelberg (Germany) andtween 5 and 18 years and a creatinine clearance (ac-
by local ethics committees. Signed informed consent wascording to Schwartz) of less than 60 mL/min/1.73 m2
obtained from the parents.body surface area (BSA). The exclusion criteria were
Run-in period. At the beginning of the run-in period,renal replacement therapy, primary metabolic disease,
all of the vitamin D preparations were discontinued,acute illness, organ (other than kidney) disease, gastroin-
whereas the usual medications (including phosphatetestinal malabsorption, and endocrine disorders (such as
binders) were regularly administered according to indi-hypoparathyroidism, diabetes mellitus, hypothyroidism,
vidual requirements (mean daily calcium carbonate sup-and hypopituitarism). In addition, any patient with hypo-
plementation was 29.1 6 41.5 mg/kg). All patients re-calcemia and hypercalcemia (serum calcium ,8.5 and
ceived instructions to restrict their dietary phosphate.11.0 mg/dL), hyperphosphatemia, or hypophosphate-
intake and were advised to keep a constant self-selectedmia (serum phosphate ,3.5 or .7.0 mg/dL), uncorrected
diet throughout the duration of the study. At the end ofacidosis (serum bicarbonate , 18 mmol/L) were also
the run-in period, the patients with iPTH values twiceconsidered ineligible for the study. A total of 20 patients
above the upper normal limit were stratified and ran-(16 males) successfully completed the entire protocol.
domized; if iPTH was still below this target limit, theTheir mean age was 13.1 6 3.3 years (range 5.1 to 16.9),
run-in period was continued for a further three weeksand they had a mean creatinine clearance value of 21.9 6
(which was necessary for one patient only).11.5 mL/min/1.73 m2 (range 7.4 to 52.7). The underlying
Study procedure. All study patients were stratified ondiseases leading to CRF were obstructive uropathy (N 5
the basis of their plasma iPTH levels and were then10), renal hypodisplasia (N 5 5), polycystic kidney dis-
randomized to one of the two treatment sequences. Theease (N 5 2), nephrophthisis (N 5 2), and Alport syn-
drome (N 5 1). stratification criteria were (1) iPTH 3 times and (2) .3
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times the upper normal limit. Using the restricted ran- ture for 10 minutes, calibration of the equipment, analy-
domization technique, the patients were assigned to re- sis of the samples, and reading of the values at a wave-
ceive two calcitriol boli: oral calcitriol first, followed by length of 460.7 nm (slit 0.7). All samples from each
IV calcitriol (N 5 10) or IV calcitriol followed by oral subject were processed and analyzed in duplicate in the
calcitriol (N 5 10). A washout period of three weeks same assay. The reproducibility of the method was evalu-
was placed between the administration of the first and ated on 60 samples re-analyzed on different days. The
the second bolus. coefficient of variance (CV) at our laboratory was 4.1%.
The study and control patients were admitted to the The Sr concentration is reported as the fraction of the
hospital, and after an overnight fast, blood was drawn absorbed dose (FAD%) contained in the extracellular
for baseline biochemical determinations. Calcitriol (1.5 fluids, assuming that this was 15% of ideal body weight,
mg/m2 BSA) was administered only to study patients according to the following formula [20]:
either orally or intravenously with Rocaltrolt capsules
(0.25 to 0.5 mg; Hoffman-La Roche, Basel, Switzerland)
FAD 5
[Sr] 3 15% of ideal body weight
Sr administered doseand Calcijext vials (1 mg/mL; Abbott Labs, Abbott Park,
IL, USA). The oral dose of calcitriol was rounded to the
The areas under the curve were calculated by meansnearest multiple of 0.25 mg. Precisely the same amount
of the trapezoidal method (Bezout integral).was used for the intravenous administration. The pa-
tients were not allowed to ingest food for the first four
Analytical methodshours following calcitriol administration.
Twenty-four hours after calcitriol administration, the The levels of serum calcium, phosphate, 1,25(OH)2D3
intestinal Sr absorption test was performed. The Sr test and Sr, and plasma iPTH were centrally determined; the
was performed without administering any calcitriol in remaining laboratory determinations were made locally.
the patients who underwent the baseline control Sr test. Serum calcium and phosphate were measured using
Washout period. During the three weeks between the an automated Hitachi analyzer. Serum 1,25(OH)2D3 wasfirst and the second calcitriol bolus, all vitamin D ana- determined by a radio receptor assay (Nichols Institute
logues were withheld, whereas all other medications
Diagnostics, San Juan Capistrano, CA, USA) with mean
were regularly administered as during the run-in period.
intra-assay and interassay coefficients of variations of 7.8Biochemical determinations. Before the administration
and 13.7%, respectively. The normal range was 18 to 62of both the first and the second bolus, baseline laboratory
pg/mL. The plasma iPTH was measured in duplicate usingdeterminations were made for serum creatinine, calcium,
a two-site IRMA (Allegro Intact PTH kit; Nichols Insti-phosphate, alkaline phosphatase, albumin, bicarbonate,
tute Diagnostics). The assay had a sensitivity of 1 pg/mL,1,25(OH)2D3, and plasma iPTH. Serum calcium, phos-
and the duplicate measurements showed a mean intra-phate, 1,25(OH)2D3, and plasma iPTH were also deter-
assay CV of 4.1%. The mean interassay CV was 5.8%.mined 1, 2, 3, 4, 6, 12, 24, 48, and 72 hours after calcitriol
administration [in the case of the IV bolus, serum
Statistical analysis1,25(OH)2D3 was also measured 5 minutes after the in-
jection]. Baseline descriptive variables are given as mean and
Intestinal strontium absorption test. The Sr absorption standard deviation, and data for 1,25(OH)2D3, Sr, and PTH
test was performed according to Reid et al [20, 24]. A are presented as least square means and standard error.
blood sample (2 mL of whole blood) was drawn for For all variables, the Shapiro-Wilk’s test for normality
baseline Sr determination. Then the standard dose of was used [25]. Student’s t-test for unpaired data was used
hexahydrated Sr chloride (8.06 mg/kg body weight, for evaluating baseline values for Sr, calcium, phosphate,
equivalent to 2.65 mg of SrCl2) was administered per os iPTH, and 1,25(OH)2D3. Statistical analysis was per-in 200 mL of deionized water to be drunk in one minute.
formed by means of the general linear model for re-
Thereafter, blood was drawn for Sr determination at
peated measures, split-plot design (SAS/PC, release 6.04;30, 60, 90, 120, 180, and 240 minutes. Between blood
SAS Institute, Cary, NC, USA). For all variables, thesamplings, the vascular access was maintained with 0.9%
sequence effect was tested to investigate whether thesaline solution (heparinized catheter). The subjects were
two sequences of treatment produced different responsesnot allowed to eat any food during the four hours of the
(validity of crossover design) [26]. The period and treat-Sr absorption test.
ment effect (treatment 5 period sequence) were ana-Strontium was measured using an atomic absorption
lyzed with multivariate tests. Nonorthogonal multiplespectrophotometer (4000 Atomic Absorption; Perkin
comparisons were tested using the Scheffe´s test [27]. AllElmer, Norwalk, CT, USA), previously calibrated with
the tests were two tailed, and the type 1 error level wasa Sr solution of known concentration. The procedure
involved stabilization of the air-acetylene flame tempera- set at 5%.
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Table 1. Biochemical findings in children with secondary
hyperparathyroidism before the administration of an oral or
intravenous (IV) calcitriol bolus
Oral IV P
CCr mL/min/1.73 m2 21.7612.0 21.6612.0 NS
Serum albumin mg/dL 4.660.6 4.760.5 NS
Serum bicarbonate mEq/L 23.063.3 21.964.0 NS
Serum calcium mg/dL 10.061.0 10.060.8 NS
Serum phosphate mg/dL 5.761.6 5.661.2 NS
Serum alkaline phosphatase
IU/mL 373 (63–1126)a 407 (53–1104)a NS
Intact PTH pg/mL 327 (102–1707)a 305 (143–2419)a NS
1,25(OH)2D3 pg/mL 24.7611.5 22.8611.5 NS
Data are given as mean 6 standard deviation or a median and range. CCr is
creatinine clearance.
Fig. 3. Box plot of the percentage decrease from baseline of intact
parathyroid hormone (iPTH) after a bolus of calcitriol (1.5 mg/m2)
given orally (h) and intravenously ( ). *P , 0.05.
AUC0–72h (4321 6 1446 vs. 3180 6 1096 pg/mL · h; P ,
0.01). Peak serum 1,25(OH)2D3 levels following oral ad-
ministration typically occurred after two to fours hours
(mode 3 hours); furthermore, serum 1,25(OH)2D3 con-
centrations remained persistently and significantly lower
after oral than after IV administration for up to 12 hours.
Serum 1,25(OH)2D3 levels returned to their baseline val-Fig. 2. Time course of 1,25(OH)2D3 serum concentration following a
calcitriol bolus (1.5 mg/m2) given orally (j) or intravenously (d). For ues after 72 hours.
intravenous calcitriol, an additional determination was performed five No significant decrease in plasma iPTH concentrationsminutes after calcitriol injection (mean 6 SEM, *P , 0.01).
was observed during the first six hours after calcitriol ad-
ministration, but they were significantly lower than at base-
line after 12 hours and remained so for up to 72 hours
RESULTS (Fig. 3). However, this decrease was not significantly
different after oral and IV bolus administration, althoughBaseline biochemistry
the maximum percentage decrease from baseline (nadir)At the end of the control period, preceding stratifica-
was significantly greater after oral administrationtion and randomization, the following laboratory find-
(246.1 6 14.8% vs. 234.3 6 22.1%, P , 0.05).ings were obtained: mean serum creatinine 4.75 6 2.5
The results were not different when patients with highmg/dL, calcium 10.1 6 0.91 mg/dL, phosphate 5.4 6 1.1
and moderately elevated iPTH plasma levels were ana-mg/dL, 1,25(OH)2D3 22.8 6 12.5 pg/mL, median iPTH
lyzed separately. There was also no correlation between327 pg/mL (range of 143 to 1323 pg/mL). Table 1 shows
iPTH values at the start and the percentage decreasethe laboratory findings immediately before the oral and
following calcitriol bolus.IV calcitriol bolus administrations. Patients who under-
Neither the oral nor the IV bolus had any significantwent the baseline Sr test (without calcitriol) had the
effect on the serum concentration of calcium and phos-following biochemical findings: mean serum creatinine
phate during the 72 hours following their administration4.3 6 1.7 mg/dL, calcium 9.4 6 0.48 mg/dL, phosphate
(data not given).5.1 6 0.93 mg/dL; 1,25(OH)2D3 19.8 6 9.7 pg/mL; and
median iPTH 201 pg/mL (range of 89 to 429 pg/mL).
Effect of calcitriol on intestinal Sr absorption
Effect of calcitriol on serum biochemistry As shown in Figure 4, the mean Sr absorption follow-
ing IV or oral calcitriol was more than 30% higher com-As expected, the time course of serum 1,25(OH)2D3
pared with control values. However, the Sr absorptionafter oral and IV calcitriol administration was substan-
was similar after the IV and oral calcitriol bolus, thetially different (Fig. 2), with the IV route leading to
results being substantially the same whether the absorp-significantly higher peak serum concentrations (282 6 90
vs. 94 6 36 pg/mL, P , 0.0001) and a higher 1,25(OH)2D3 tion was analyzed in terms of Sr peak concentrations or
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Fig. 4. Time course of Sr fractional absorption without calcitriol (m)
and 24 hours after a calcitriol bolus (1.5 mg/m2) given orally (j) and
intravenously (s) in children with secondary hyperparathyroidism
(mean 6 SEM).
the SrAUC0–240 min. The Sr peak concentrations without
calcitriol and after oral and IV administration were
12.6 6 1.5, 17.5 6 6.31, and 18.7 6 9.25 FAD%, respec-
tively, and the SrAUC0–240 min values were 2165 6 176,
2867 6 1101, and 3117 6 1581 FAD% · min. The individ-
ual results of SrAUC0–240 min in patients are depicted in
Figure 5. The results were not different when the analysis
Fig. 5. Individual SrAUC0–240 min following the administration of an oralwas done separately for patients with high and moder- and an IV calcitriol bolus. Symbols indicate the patient’s order of
ately elevated iPTH levels (data not given). calcitriol administration: oral followed by intravenous (h); intravenous
followed by oral (s).As shown in Figure 6A, the SrAUC0–240 min after an oral
bolus of calcitriol significantly correlated with creatinine
clearance; no correlation was observed after IV calcitriol
(Fig. 6B). percalcemia [13]. However, all studies comparing IV and
oral calcitriol [16–19] do not allow definite conclusions
to be drawn, since the calcitriol dose and the amount ofDISCUSSION
prescribed phosphate binders were not fixed, and/or theThe present study in children with CRF gives clear
patients were not adequately randomized in terms ofevidence that intestinal calcium absorption measured by
dialysis modality and/or the degree of hyperparathyroid-stable Sr, as a surrogate marker for calcium, is not sig-
ism. Furthermore, in these studies, hypercalcemia maynificantly different after a single calcitriol oral or IV
have occurred not only as a result of intestinal calciumbolus. Furthermore, it shows that plasma iPTH levels
absorption, but also (and even primarily) as a conse-become significantly lower 12 hours after the calcitriol
quence of low bone turnover caused by calcitriol therapy.bolus and remain low for up to 72 hours regardless of
The present crossover study was designed to measurethe route of administration.
intestinal calcium absorption following a single oral orIntravenous calcitriol bolus therapy has been recom-
IV bolus of calcitriol given to the same patients.mended for the control of secondary renal hyperparathy-
We used stable Sr as a surrogate calcium marker forroidism since 1984 [11]. One advantage that has been
the measurement of intestinal calcium absorption. Thisclaimed is the avoidance of any direct contact between
method is safe and suitable for repeated measurementsintestinal epithelial cells and calcitriol during the intesti-
(particularly in children). It was first described by Reidnal absorption process, thus reducing the risk of hyper-
et al, who demonstrated a very close correlation betweencalcemia [11, 12]. Indeed, the results of some clinical
Sr and calcium absorption (r 5 0.93) co-measured usingtrials have led to the conclusion that the IV route of
administration is associated with fewer episodes of hy- 45Ca [20]. The fractional absorption of Sr was lower in
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Fig. 6. Relationship between creatinine clearance (CCr) and Sr intestinal absorption measured 24 hours after an oral (A) and an intravenous (B)
calcitriol bolus. SrAUC0–240 min is the area under the Sr fractional absorption time curve.
absolute terms than that of 45Ca, but the time course by differential effects of the IV or oral calcitriol bolus
on renal Sr excretion. Although we did not measure thisvery closely resembles that of radioactive calcium. Re-
cently, we [24] and many others [20–23] have shown that effect, they are not relevant since Sr absorption was
measured for only four hours following its administra-the Sr test is an easy, highly reproducible, and reliable
method for estimating the intestinal absorption of calcium tion. The renal loss within this time is very small, and
we believe it can be neglected for the calculation of FAD.in healthy volunteers and in patients with CRF [28].
In the present study, Sr absorption was measured 24 Our results also showed that Sr absorption following an
oral calcitriol bolus was significantly correlated with creati-hours after the bolus administration of calcitriol on the
basis of the following considerations: 1,25(OH)2D3 in- nine clearance. Studies in adults with CRF have demon-
strated that intestinal calcium absorption decreases withfluences the intestinal calcium absorption by rapid non-
genomic actions on the cellular membrane [29–31] and by the progression of renal failure and the decrease in serum
calcitriol concentration [36, 37].activating a specific transport system mainly in the duode-
num [32], which involves gene activation and protein Our study extends these findings by demonstrating
that the correlation between glomerular filtration rate andsynthesis (genomic effect) [33–35]. In calcium-deprived
and vitamin D-depleted rats, the calcium transport re- Sr absorption remained after an oral dose of calcitriol,
thus showing an increasing insensitivity to calcitriol withsponse to a single injection of calcitriol is biphasic [29]:
The early response is characterized by a relatively rapid decreasing renal function. It is of interest to note that
no correlation between creatinine clearance and Sr ab-rise to a peak at six hours followed by a rapid decline.
The second or late response becomes apparent approxi- sorption was observed when calcitriol was administered
as an IV bolus, because Sr absorption fell within themately 12 hours after administration, reaches a peak at
24 hours, and maintains this level for at least 72 hours. normal range despite a low filtration rate (at least in a
subgroup of patients).In vitamin D-repleted animals, rapid nongenomic action
of 1,25(OH)2D3 (transcaltachia) developed within a few The second important result of the present study is
the finding that a single bolus of calcitriol can lower plasmaminutes [30]. In our previous studies on healthy volun-
teers, no early effect of a calcitriol bolus (1.5 mg/m2 as iPTH levels for up to 72 hours. This confirms our previ-
ous observations in children [10] and adults [9] and ex-used in the present study) on Sr absorption could be
detected, whereas Sr absorption significantly increased tends these with the notion that the time course and
magnitude of iPTH suppression are not influenced by theby 35% after 24 hours [24].
In the present study of children with CRF, the mean Sr route of calcitriol administration. With the limitations of
the method used, we did not see any systematic changeabsorption following calcitriol administration was about
one third higher than control values, indicating the effi- in serum calcium and phosphate levels during the entire
study period.cacy of calcitriol treatment. However, mean basal values
for healthy adults [24] were not reached. There was no The effect of calcitriol on iPTH was noted only 12 hours
after the first administration, thus pointing to a genomicdifference with the oral or IV administration of calcitriol.
One might argue that the results have been influenced effect. We have likewise demonstrated by means of decon-
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parathyroid cell proliferation in experimental uremia. Kidney Intvolution analysis in healthy volunteers that intravenous
35:1049–1056, 1989
calcitriol has no “early” (nongenomic) effects on pulsatile 8. Delmez JA, Slatopolsky E: Clinical review 20: Advances in the
pathogenesis and therapy of uremic hyperparathyroidism. J Clinand tonic PTH secretion, whereas both were significantly
Endocrinol Metab 72:735–739, 1991decreased after prolonged calcitriol administration [38].
9. Seidel S, Herrmann P, Klaus G, Mehls O, Schmidt-Gayk H,
This prolonged decrease in iPTH is in agreement with Ritz E: Kinetics of serum 1,84 iPTH after high dose of calcitriol
in uremic patients. Clin Nephrol 39:210–213, 1993the prolonged decrease in mRNA for pre-pro-PTH after
10. Klaus G, Schmidt-Gayk H, Roth HJ, Ritz E, Mehls O: Single-the injection of a calcitriol bolus in rats [4, 39].
dose calcitriol and changes of plasma 1,84iPTH in uremic children.
The effects of intravenous calcitriol have been related Adv Perit Dial 10:261–266, 1994
11. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martinto (1) higher peak concentrations and greater occupancy
KJ: Marked suppression of hyperparathyroidism by intravenousof the vitamin D receptor, and (2) modulation and up-
administration of 1,25-dihydroxy-cholecalciferol in uremic pa-
regulation of the vitamin D receptor [40]. The present tients. J Clin Invest 74:2136–2143, 1984
12. Coburn JW: Use of oral and parenteral calcitriol in the treatmentstudy and the clinical experience that oral bolus calcitriol
of renal osteodystrophy. Kidney Int 38:54–61, 1990therapy is highly effective and even equi-effective in head-
13. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrad
on comparison studies [16, 19] suggest that the intermit- DJ: Intravenous calcitriol in the treatment of refractory osteite
fibrosa of chronic renal failure. N Engl J Med 321:274–279, 1989tent modality of administration rather than the peak con-
14. Claris-Appiani A, Ardissino GL, Tischer MC, Bettinelli A,centration of calcitriol is responsible for the efficacy of
Tirelli AS, Dacco` V, Castiglioni G, Pecchio F, Cunazza M,
intravenous treatment. Assael BM: Intramuscular calcitriol for uremic children with se-
vere hyperparathyroidism and hypercalcemia. Pediatr NephrolOur study was performed as an acute short-term study
8:719–723, 1994comparing the effects of a single oral calcitriol bolus versus
15. Klaus G, Mehls O, Hinderer J, Ritz E: Is intermittent oral
a single IV calcitriol bolus. The question as to whether calcitriol safe and effective in renal secondary hyperparathyroid-
ism? Lancet 337:800–801, 1991the results can be extended to repeated and prolonged
16. Quarles LD, Yohay DA, Carrol BA, Spritzer CE, Minda SA,application of calcitriol bolus treatment cannot be an-
Bartholomay D, Lobaugh BA: Prospective trial of pulse oral
swered with certainty at this moment. Controlled clinical versus intravenous calcitriol treatment of hyperparathyroidism in
ESRD. Kidney Int 45:1710–1721, 1994studies seem to confirm that IV calcitriol is not superior
17. Herrmann P, Ritz E, Schmidt-Gayk H, Schafer I, Geyer J, Non-to oral calcitriol in suppressing iPTH levels. Based on
nast-Daniel B, Koch KM, Weber U, Horl W, Haas-Worle A,
the results of our study, it cannot be assumed that the Kuhn K, Bierther B, Schneider P: Comparison of intermittent
and continuous oral administration of calcitriol in dialysis patients:IV calcitriol route is superior to the oral one with regard
A randomized prospective trial. Nephron 67:48–53, 1994to intestinal calcium absorption.
18. Mazzaferro S, Pasquali M, Ballanti P, Bonucci Z, Sidanza P,
Sardella D, Taggi F, Coen G: Intravenous versus oral calcitriol
therapy in renal osteodystrophy: Results of a prospective, pulsedACKNOWLEDGMENTS
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